Importing pharmaceutical ingredients — Active Pharmaceutical Ingredients (APIs), bulk drugs, and excipients — to India requires a Drug Licence from the Central Drugs Standard Control Organisation (CDSCO), strict cold chain handling for temperature-sensitive materials, and customs clearance under Chapter 30 Harmonized System (HS) codes. Sea Air Cargo Systems handles air freight and customs clearance for pharma importers.
To import pharmaceutical ingredients into India legally, importers must secure an Import Registration Certificate (Form 41) and an Import License (Form 10) from the Central Drugs Standard Control Organization (CDSCO) under the Central Drugs and Cosmetics Rules. Cargo must pass customs under strict temperature-controlled logistics through specified sea and airports. Sea Air Cargo Systems provides end-to-end air freight coordination, cold chain monitoring, and expert customs clearance at major Indian portals.
Pharmaceutical materials imported into India fall into five regulated categories — APIs, bulk drugs, excipients, intermediates, and biologics — each mapped to specific HS codes under Chapters 29 and 30 that determine licensing requirements, duty rates, and cold chain handling rules.
Under Indian Customs regulations, import substances are categorized into distinct therapeutic and raw material buckets. Understanding these definitions is vital for choosing the correct tariff classification, which dictates the applicable Customs duty rates, licensing standards, and handling parameters for your cargo:
Indian Import Customs uses highly structured HS Code groupings spanning across Chapter 29 (Organic Chemicals) and Chapter 30 (Pharmaceutical Products) of the national tariff schedule. Submitting correct HS classifications prevents administrative penalties, delays, and dynamic audits during trade entries. Key categories include:
Commercial import of pharmaceutical ingredients requires two CDSCO authorizations: an Import Registration Certificate (Form 41) for the foreign manufacturing facility and an Import Licence (Form 10) for the Indian importer, both filed through the online SUGAMP portal. No drug raw material or biological agent can clear customs without these registrations under the Drugs and Cosmetics Act, 1940.
The CDSCO (Central Drugs Standard Control Organization) is India's national regulatory body for cosmetics, pharmaceuticals, and medical devices. Under the Drugs and Cosmetics Act of 1940, no commercial entity can access, buy, or transport imported drug substances without formal approvals. The critical steps for registration include:
A Local Authorized Agent (LAA) is a registered Indian business entity designated by an overseas manufacturer to act as their legal representative in India. The LAA is responsible for filing registration dossiers, communicating with CDSCO officers through the SUGAMP dashboard, tracking approvals, and facilitating drug safety testing coordinates inside Indian territories.
Pharmaceutical ingredients imported into India attract a Basic Customs Duty (BCD) of 7.5–10% under Chapters 29 and 30, plus a 10% Social Welfare Surcharge (SWS) on the BCD amount and 12–18% Integrated Goods and Services Tax (IGST) on the total assessable value. Customs duties are calculated based on the transaction value of the shipment under CBIC valuation guidelines.
The total landing cost of bulk pharmaceutical compounds is shaped heavily by basic duties and regulatory taxes under current tariff directives. The total effective duty involves combining multiple tax layers. The BCD (Basic Customs Duty) is the fundamental import duty under the Customs Act of 1962, whereas the IGST (Integrated Goods and Services Tax) is an ad-valorem tax levied on the combined assessment value including the BCD layer.
While the standard BCD tariff can reach 10%, certain essential APIs and critical treatments benefit from special duty exemptions. For instance, cancer medications, immunizing vaccines, and raw products listed in Central Customs Notification No. 50/2017-Customs enjoy a reduced BCD rate of 0% or 2.5% to maintain healthcare affordability in local markets.
| Product Category | Tariff Chapter | Basic Customs Duty (BCD) | IGST Rate | Social Welfare Surcharge (SWS) |
|---|---|---|---|---|
| Active Pharmaceutical Ingredients (APIs) | Chapter 29 | 7.5% - 10.0% | 12.0% | 10.0% of BCD value |
| Pharmaceutical Excipients | Chapter 29 / 35 | 7.5% | 18.0% | 10.0% of BCD value |
| Critical Vaccines (Human Medicine) | Chapter 30 (3002) | 10.0% (Exemptions apply) | 5.0% - 12.0% | 10.0% of BCD value |
| Life-Saving Drugs (Oncology, HIV) | Chapter 30 (3004) | 0.0% - 2.5% | 5.0% - 12.0% | Exempt |
| Bulk Drug Intermediates | Chapter 29 | 7.5% - 10.0% | 18.0% | 10.0% of BCD value |
Temperature-sensitive pharmaceutical imports must maintain one of three verified brackets: deep frozen (-20°C to -80°C), refrigerated (+2°C to +8°C), or controlled ambient (+15°C to +25°C), tracked by calibrated data loggers throughout transit. End-to-end temperature preservation aligns with Good Distribution Practices (GDP) and certified air logistics facilities to prevent therapeutic decay of complex chemical payloads.
Temperature-sensitive APIs and raw biologics are highly vulnerable to environmental changes during transport. A change of even 2 degrees can destroy an entire batch. To prevent this, shipping arrangements must meet IATA CEIV Pharma (Center of Excellence for Independent Validators in Pharma Logistics) standards to protect your cargo at airport transit points. Standard temperature brackets include:
The AISATS Coolport is a specialized high-performance perishables cargo handling facility based at Kempegowda International Airport (BLR) in Bengaluru. It offers dedicated temperature-controlled chambers, cold-dock access, and instant CDSCO inspection hubs, enabling seamless, temperature-secured import clearances for Karnataka pharma operations.
Indian pharma cargo clearance requires seven mandatory documents: commercial invoice, packing list, Air Waybill (AWB) or Bill of Lading (BoL), Certificate of Origin (COO), Certificate of Analysis (COA), valid CDSCO Form 10/41 registrations, and Material Safety Data Sheet (MSDS), all filed digitally through the ICEGATE (Indian Customs Electronic Gateway) portal. Any variance in spelling, chemical names, or registration codes between transport files and CDSCO registrations can lead to shipping delays. The documentation package must include:
Importing APIs into India takes 9–12 months for initial CDSCO registrations (Form 41 and Form 10) and 24–72 hours for customs clearance once documents are pre-filed on ICEGATE. Successfully clearing APIs and raw materials involves a systematic approach, from foreign registration to local delivery, coordinated by a specialist licensed Customs House Agent (CHA).
Regulatory compliance requires complete alignment across foreign manufacturing, international shipping, air handling, and CBIC valuation systems before delivery to production facilities.
Apply for and secure an Import Registration Certificate (Form 41) for the international production facility and a corresponding Import Licence (Form 10) for the domestic importing entity. This process is completed online via CDSCO's SUGAMP portal, referencing valid wholesale drug licences and the local entity's Import Export Code (IEC).
Obtain a valid copy of the foreign site's WHO-GMP Certificate along with comprehensive, batch-level Certificate of Analysis (COA) documents. Ensure that physical label markers, container batch serialization, and chemical specifications match the official registration documents.
Coordinate container configurations with your freight forwarder. For temperature-sensitive materials, route the cargo with IATA CEIV-certified air carriers. Use calibrated active or passive thermal shippers, and set up real-time temperature tracking to monitor temperature stability throughout transit.
Create and submit an advance Bill of Entry (BoE) on the national ICEGATE portal 48 to 72 hours before the aircraft lands. This advance filing provides the regulatory system with the HS Codes, product generic names, batch numbers, and CDSCO registration details needed for rapid risk profiling.
Provide physical cargo access and transport documents to the port's ADC (Assistant Drug Controller). The officer will verify batch labels, check temperature logs, and draw samples for analysis. For a new manufacturer's first three imports, the ADC will require physical testing at an approved national drug laboratory before commercial clearance.
Once you receive the CDSCO release note, submit customs valuations to clear any Risk Management System (RMS) flags. Pay all Basic Customs Duties (BCD) and IGST liabilities, obtain the "Out of Charge" (OOC) order from Customs, and arrange temperature-controlled transport to deliver the cargo to your logistics team.
The three most common causes of pharma import delays are mismatched batch numbers across documents (triggering ADC quarantine), arrival at non-designated ports lacking CDSCO inspection infrastructure (forcing re-routing at ₹50,000–₹2,00,000), and unrecorded temperature excursions during transit (leading to batch destruction). Regulatory compliance is exceptionally strict when clearing chemical bulk materials. The most common delays and seizures stem from avoidable administrative and operational mistakes:
If physical carton labels show a batch number that differs even slightly from the Certificate of Analysis (COA) or Commercial Invoice, the Assistant Drug Controller (ADC) will halt and quarantine the cargo. Any discrepancy in chemical descriptions, supplier names, or brand designations will trigger a complete administrative hold.
Under Rule 43A of the Drugs and Cosmetics Rules, pharmaceuticals and bulk drugs can only enter India through specific designated gateways. If a cargo plane lands at an airport or ocean terminal that lacks a CDSCO Port Health Office (PHO) or ADC infrastructure, the customs system cannot clear the cargo, resulting in expensive re-routing or forced re-exportation.
A shipping temperature that falls out of range during transit can ruin biological bases and vaccines. If a datalogger shows a temperature excursion at an intermediate airport hub and the importer lacks the validation data to prove product stability, the CDSCO officer can refuse to grant importation clearance, forcing terminal destruction of the batch.
You need two CDSCO authorizations: an Import Registration Certificate (Form 41) for the foreign manufacturing facility and an Import License (Form 10) for the domestic importer. These are issued exclusively by the Central Drugs Standard Control Organization (CDSCO) — India's national drug regulator under the Ministry of Health — via the SUGAMP digital platform. All applications require a valid Import Export Code (IEC) issued by DGFT and wholesale drug licenses (Form 20-B and Form 21-B). Initial Form 41 approval takes 9–12 months, and Form 10 takes 3–6 months.
Obtaining initial drug import registrations through the CDSCO involves two primary phases. The Import Registration Certificate (Form 41) for a foreign site takes 9 to 12 months for review, verification, and technical evaluation. Once the facility approval is secured, applying for the actual Import License (Form 10) for individual product batches takes approximately 3 to 6 months. For expedited clearances, using an accredited logistics specialist like Sea Air Cargo Systems reduces document filing errors that cause regulatory delays.
Most imported APIs and bulk drug substances fall under Chapters 29 and 30 of the Indian Customs Tariff, carrying a Basic Customs Duty (BCD) that ranges between 5% and 10% (CBIC Tariff, 2026). Additionally, imports incur a 12% Integrated Goods and Services Tax (IGST) and a 10% Social Welfare Surcharge (SWS) calculated on the primary duty. Select critical APIs, oncology therapeutics, and life-saving drugs enjoy special concessions, with some reduced to a 0% BCD under Notification No. 50/2017-Customs.
Controlled shipping temperature ranges apply to standard biological products, immunoglobulins, living cultures, and dynamic diagnostic reagents under Chapter 30 codes. Vaccines and select protein-based pharmaceutical compounds require cold packaging engineered to sustain +2°C to +8°C. Advanced biologics, deep-freeze active substances, and genetic vector substances require dry ice or liquid nitrogen setups targeting -20°C to -80°C. Quality assurance requires calibrated physical data loggers to prove zero temperature deviations during flight and port handling.
Yes, you can import generic pharmaceutical ingredients and APIs from China, provided the processing manufacturing facility is registered with CDSCO and holds a valid Form 41 certificate. Importers must execute systematic testing across the initial 3 consignments under direct monitoring from the port's Assistant Drug Controller (ADC). Every shipment must arrive with detailed batch Certificates of Analysis (COA) issued by WHO-GMP certified facilities matching recognized European, United States, or Indian Pharmacopoeia monographs.
There is no set statutory minimum order quantity (MOQ) imposed by Indian Customs or CDSCO regulations for importing bulk pharmaceutical ingredients. Importers can bring in cargo volumes matching their registered manufacturing capacities or wholesale licenses. However, transport efficiency, specialized thermal packaging, active cooling container rental tariffs, and minimum handling fees at dedicated air cargo terminal coolports generally make sub-100 kg shipments financially unviable for complex cold-chain logistics.
Get your CDSCO import clearances and API shipping handled with zero compliance delays.